Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
New weakness to target breast cancer cells discovered
Researchers at The Institute of Cancer Research, London, have uncovered a hidden weakness in some breast cancer tumours that could lead to smarter treatment decisions.
945x532.png?sfvrsn=310c2acf_2 "Cell Division-(green-4-3)945x532")
New protective role of gene frequently mutated in cancer uncovers potential therapeutic target
New research into how cancer develops has uncovered more detail about the importance of the centromere, a region of human DNA that has a critical role in effective cell division.
-mucinous-ovarian-tumour---945x532.jpg?sfvrsn=5e9bb32b_2 "Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour - 945x532")
Smarter chemotherapy approach could delay drug resistance in ovarian cancer
Adaptive chemotherapy – a personalised approach to giving chemotherapy – can prolong survival in lab models of ovarian cancer, according to new results published in the journal Cancer Research.
ICR welcomes plans for £1 billion development to create world-leading cancer research district in Sutton
The Institute of Cancer Research has welcomed new plans to deliver around one million square feet of state-of-the-art research and laboratory space for life-sciences companies in Sutton, south London, where they will be located next door to our researchers.